{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T22:00:21Z","timestamp":1782943221503,"version":"3.54.5"},"reference-count":98,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2020,9,16]],"date-time":"2020-09-16T00:00:00Z","timestamp":1600214400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomedicines"],"abstract":"<jats:p>This manuscript presents quantitative findings on the actual effectiveness of terminal complement component 5 (C5) inhibitors and complement component 1 (C1) esterase inhibitors through their formal and common \u201coff-label\u201d (compassionate) indications. The results emanated from pairwise and network meta-analyses to present evidence until September 2019. Clinical trials (CT) and real-life non-randomized studies of the effects of interventions (NRSI) are consistent on the benefits of C5 inhibitors and of the absence of effects of C1 esterase inhibitors (n = 7484): Mathematically, eculizumab (surface under the cumulative ranking area (SUCRA) &gt;0.6) and ravulizumab (SUCRA \u2265 0.7) were similar in terms of their protective effect on hemolysis in paroxysmal nocturnal hemoglobinuria (PNH), thrombotic microangiopathy (TMA) in atypical hemolytic uremic syndrome (aHUS), and acute kidney injury (AKI) in aHUS, in comparison to pre-\/off-treatment state and\/or placebo (SUCRA &lt; 0.01), and eculizumab was efficacious on thrombotic events in PNH (odds ratio (OR)\/95% confidence interval (95% CI) in CT and real-life NRSI, 0.07\/0.03 to 0.19, 0.24\/0.17 to 0.33) and chronic kidney disease (CKD) occurrence\/progression in PNH (0.31\/0.10 to 0.97, 0.66\/0.44 to 0.98). In addition, meta-analysis on clinical trials shows that eculizumab mitigates a refractory generalized myasthenia gravis (rgMG) crisis (0.29\/0.13 to 0.61) and prevents new acute antibody-mediated rejection (AMR) episodes in kidney transplant recipients (0.25\/0.13 to 0.49). The update of findings from this meta-analysis will be useful to promote a better use of complement inhibitors, and to achieve personalization of treatments with this class of drugs.<\/jats:p>","DOI":"10.3390\/biomedicines8090355","type":"journal-article","created":{"date-parts":[[2020,9,16]],"date-time":"2020-09-16T20:44:13Z","timestamp":1600289053000},"page":"355","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["The Inhibition of Complement System in Formal and Emerging Indications: Results from Parallel One-Stage Pairwise and Network Meta-Analyses of Clinical Trials and Real-Life Data Studies"],"prefix":"10.3390","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5055-3493","authenticated-orcid":false,"given":"Coralina","family":"Bernuy-Guevara","sequence":"first","affiliation":[{"name":"Pharmacological Big Data Laboratory, University of Valladolid, 47005 Valladolid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassib","family":"Chehade","sequence":"additional","affiliation":[{"name":"Pediatric Nephrology Unit, Lausanne University Hospital and University of Lausanne, 1100 Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yannick D.","family":"Muller","sequence":"additional","affiliation":[{"name":"Transplantation Center, Lausanne University Hospital and University of Lausanne, 1100 Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1654-0488","authenticated-orcid":false,"given":"Julien","family":"Vionnet","sequence":"additional","affiliation":[{"name":"Transplantation Center, Lausanne University Hospital and University of Lausanne, 1100 Lausanne, Switzerland"},{"name":"King\u2019s College London, London WC2R 2LS, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Cachat","sequence":"additional","affiliation":[{"name":"Pediatric Nephrology Unit, Lausanne University Hospital and University of Lausanne, 1100 Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Guzzo","sequence":"additional","affiliation":[{"name":"Transplantation Center, Lausanne University Hospital and University of Lausanne, 1100 Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7670-3699","authenticated-orcid":false,"given":"Carlos","family":"Ochoa-Sangrador","sequence":"additional","affiliation":[{"name":"Clinical Epidemiology Support Office, Sanidad de Castilla y Le\u00f3n, 49022 Zamora, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7566-5678","authenticated-orcid":false,"given":"F. Javier","family":"\u00c1lvarez","sequence":"additional","affiliation":[{"name":"Pharmacological Big Data Laboratory, University of Valladolid, 47005 Valladolid, Spain"},{"name":"Ethics Committee of Drug Research\u2013east Valladolid area, University Clinical Hospital of Valladolid, 47005 Valladolid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Teta","sequence":"additional","affiliation":[{"name":"Department of Nephrology, H\u00f4pital du Valais, 1950 Sion, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D\u00e9bora","family":"Mart\u00edn-Garc\u00eda","sequence":"additional","affiliation":[{"name":"Clinical Nephrology Unit, University Clinical Hospital of Valladolid, 47003 Valladolid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7176-2115","authenticated-orcid":false,"given":"Marcel","family":"Adler","sequence":"additional","affiliation":[{"name":"Center for Medical Oncology &amp; Hematology, Hospital Thun, 3600 Thun, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F\u00e9lix J.","family":"de Paz","sequence":"additional","affiliation":[{"name":"Pharmacological Big Data Laboratory, University of Valladolid, 47005 Valladolid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9993-9998","authenticated-orcid":false,"given":"Frank","family":"Lizaraso-Soto","sequence":"additional","affiliation":[{"name":"Pharmacological Big Data Laboratory, University of Valladolid, 47005 Valladolid, Spain"},{"name":"Centro de Investigaci\u00f3n en Salud P\u00fablica, Instituto de Investigaci\u00f3n de la Facultad de Medicina Humana, Universidad de San Mart\u00edn de Porres, Lima 15024, Peru"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Pascual","sequence":"additional","affiliation":[{"name":"Transplantation Center, Lausanne University Hospital and University of Lausanne, 1100 Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3110-692X","authenticated-orcid":false,"given":"Francisco","family":"Herrera-G\u00f3mez","sequence":"additional","affiliation":[{"name":"Pharmacological Big Data Laboratory, University of Valladolid, 47005 Valladolid, Spain"},{"name":"Transplantation Center, Lausanne University Hospital and University of Lausanne, 1100 Lausanne, Switzerland"},{"name":"Centro de Investigaci\u00f3n en Salud P\u00fablica, Instituto de Investigaci\u00f3n de la Facultad de Medicina Humana, Universidad de San Mart\u00edn de Porres, Lima 15024, Peru"},{"name":"Department of Nephrology, Hospital Virgen de la Concha, 49022 Zamora, Spain"},{"name":"Castile and Le\u00f3n\u2019s Research Consolidated Unit n\u00b0 299, 47011 Valladolid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,9,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/ni.1923","article-title":"Complement: A key system for immune surveillance and homeostasis","volume":"11","author":"Ricklin","year":"2010","journal-title":"Nat. Immunol."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Sheridan, D., Yu, Z.-X., Zhang, Y., Patel, R., Sun, F., Lasaro, M.A., Bouchard, K., Andrien, B., Marozsan, A., and Wang, Y. (2018). Design and preclinical characterization of ALXN1210: A novel anti-C5 antibody with extended duration of action. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0195909"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1097\/TP.0000000000002717","article-title":"Update on C1 Esterase Inhibitor in Human Solid Organ Transplantation","volume":"103","author":"Berger","year":"2019","journal-title":"Transplant"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1016\/S0140-6736(18)30583-X","article-title":"C1 esterase inhibitor concentrates and attenuated androgens","volume":"391","author":"Muller","year":"2018","journal-title":"Lancet"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/nrneph.2017.156","article-title":"The renaissance of complement therapeutics","volume":"14","author":"Ricklin","year":"2018","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/nrneph.2016.70","article-title":"Complement in disease: A defence system turning offensive","volume":"12","author":"Ricklin","year":"2016","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.clim.2015.08.009","article-title":"Applying complement therapeutics to rare diseases","volume":"161","author":"Reis","year":"2015","journal-title":"Clin. Immunol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.molimm.2017.05.013","article-title":"Complement in clinical medicine: Clinical trials, case reports and therapy monitoring","volume":"89","author":"Ricklin","year":"2017","journal-title":"Mol. Immunol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/2046-4053-3-35","article-title":"Observational evidence and strength of evidence domains: Case examples","volume":"3","author":"Oneil","year":"2014","journal-title":"Syst. Rev."},{"key":"ref_10","first-page":"1","article-title":"Cholesterol-Lowering Treatment in Chronic Kidney Disease: Multistage Pairwise and Network Meta-Analyses","volume":"9","author":"Chimeno","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_11","unstructured":"Higgins, J.P.T., and Green, S. (2011). Cochrane Handbook for Systematic Reviews of Interventions\u2014Version 5.1.0., The Cochrane Collaboration."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: A tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/2046-4053-3-110","article-title":"A Microsoft-Excel-based tool for running and critically appraising network meta-analyses\u2014An overview and application of NetMetaXL","volume":"3","author":"Brown","year":"2014","journal-title":"Syst. Rev."},{"key":"ref_14","unstructured":"(2008). Systematic Reviews: Centre for Reviews and Dissemination\u2019s (CRD) Guidance for Undertaking Reviews in Health Care, University of York."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"g7647","DOI":"10.1136\/bmj.g7647","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: Elaboration and explanation","volume":"350","author":"Shamseer","year":"2015","journal-title":"BMJ"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann. Intern. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1056\/NEJMoa031688","article-title":"Effect of Eculizumab on Hemolysis and Transfusion Requirements in Patients with Paroxysmal Nocturnal Hemoglobinuria","volume":"350","author":"Hillmen","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1182\/blood-2005-02-0564","article-title":"Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria","volume":"106","author":"Hill","year":"2005","journal-title":"Blood"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1056\/NEJMoa061648","article-title":"The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal Hemoglobinuria","volume":"355","author":"Hillmen","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1182\/blood-2007-06-094136","article-title":"Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria","volume":"111","author":"Brodsky","year":"2008","journal-title":"Blood"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/bjh.12347","article-title":"Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria","volume":"162","author":"Hillmen","year":"2013","journal-title":"Br. J. Haematol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"4123","DOI":"10.1182\/blood-2007-06-095646","article-title":"Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria","volume":"110","author":"Hillmen","year":"2007","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/ajh.21757","article-title":"Long-term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria","volume":"85","author":"Hillmen","year":"2010","journal-title":"Am. J. Hematol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s12185-010-0748-9","article-title":"Safety and efficacy of the terminal complement inhibitor eculizumab in Japanese patients with paroxysmal nocturnal hemoglobinuria: The AEGIS Clinical Trial","volume":"93","author":"Kanakura","year":"2011","journal-title":"Int. J. Hematol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1007\/s12185-013-1404-y","article-title":"Long-term efficacy and safety of eculizumab in Japanese patients with PNH: AEGIS trial","volume":"98","author":"Kanakura","year":"2013","journal-title":"Int. J. Hematol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1182\/blood-2018-09-876136","article-title":"Ravulizumab (ALXN1210) vs. eculizumab in adult patients with PNH naive to complement inhibitors: The 301 study","volume":"133","author":"Lee","year":"2019","journal-title":"Blood"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1182\/blood-2018-09-876805","article-title":"Ravulizumab (ALXN1210) vs. eculizumab in C5-inhibitor\u2013experienced adult patients with PNH: The 302 study","volume":"133","author":"Kulasekararaj","year":"2019","journal-title":"Blood"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"922","DOI":"10.3324\/haematol.2013.093161","article-title":"Baseline characteristics and disease burden in patients in the International Paroxysmal Nocturnal Hemoglobinuria Registry","volume":"99","author":"Schrezenmeier","year":"2014","journal-title":"Haematologica"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1111\/imj.13160","article-title":"Changing prognosis in Paroxysmal Nocturnal Haemoglobinuria disease subcategories; an analysis of International PNH Registry","volume":"46","author":"Schrezenmeier","year":"2016","journal-title":"Intern. Med. J."},{"key":"ref_30","first-page":"e76","article-title":"Different clinical characteristics of paroxysmal nocturnal hemoglobinuria in pediatric and adult patients","volume":"102","author":"Muus","year":"2016","journal-title":"Haematologica"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"E37","DOI":"10.1002\/ajh.25334","article-title":"Effectiveness of eculizumab in patients with paroxysmal nocturnal hemoglobinuria (PNH) with or without aplastic anemia in the International PNH Registry","volume":"94","author":"Lee","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s12185-019-02699-7","article-title":"Comparative study on baseline clinical characteristics of Asian versus non-Asian patients with paroxysmal nocturnal hemoglobinuria","volume":"110","author":"Sakurai","year":"2019","journal-title":"Int. J. Hematol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1007\/s12185-016-2065-4","article-title":"Interim analysis of post-marketing surveillance of eculizumab for paroxysmal nocturnal hemoglobinuria in Japan","volume":"104","author":"Ninomiya","year":"2016","journal-title":"Int. J. Hematol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"207","DOI":"10.5045\/br.2017.52.3.207","article-title":"Efficacy of eculizumab in paroxysmal nocturnal hemoglobinuria patients with or without aplastic anemia: Prospective study of a Korean PNH cohort","volume":"52","author":"Choi","year":"2017","journal-title":"Blood Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"214","DOI":"10.3346\/jkms.2016.31.2.214","article-title":"Predictive Factors of Mortality in Population of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH): Results from a Korean PNH Registry","volume":"31","author":"Jang","year":"2016","journal-title":"J. Korean Med. Sci."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s00277-015-2511-z","article-title":"Distinct subgroups of paroxysmal nocturnal hemoglobinuria (PNH) with cytopenia: Results from South Korean National PNH Registry","volume":"95","author":"Kim","year":"2016","journal-title":"Ann. Hematol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1007\/s00277-019-03735-6","article-title":"Clinical implication of renal dysfunction during the clinical course in patients with paroxysmal nocturnal hemoglobinuria: A longitudinal analysis","volume":"98","author":"Kim","year":"2019","journal-title":"Ann. Hematol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1002\/ajh.24278","article-title":"Impact of eculizumab treatment on paroxysmal nocturnal hemoglobinuria: A treatment versus no-treatment study","volume":"91","author":"Loschi","year":"2016","journal-title":"Am. J. Hematol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1182\/blood-2008-01-133918","article-title":"Paroxysmal nocturnal hemoglobinuria: Natural history of disease subcategories","volume":"112","author":"Mary","year":"2008","journal-title":"Blood"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s00277-017-3059-x","article-title":"Presence of acute and chronic renal failure in patients with paroxysmal nocturnal hemoglobinuria: Results of a retrospective analysis from the Spanish PNH Registry","volume":"96","author":"Villegas","year":"2017","journal-title":"Ann. Hematol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/ejh.12346","article-title":"Paroxysmal nocturnal hemoglobinuria: A single Spanish center\u2019s experience over the last 40 yr","volume":"93","author":"Ojeda","year":"2014","journal-title":"Eur. J. Haematol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.medcli.2010.09.035","article-title":"Paroxysmal nocturnal hemoglobinuria therapy with eculizumab: Spanish experience","volume":"137","author":"Rubio","year":"2011","journal-title":"Med. Clin. Barc."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.kjms.2017.05.011","article-title":"Distinct clinical characteristics of paroxysmal nocturnal hemoglobinuria in patients in Southern Taiwan: A multicenter investigation","volume":"33","author":"Wang","year":"2017","journal-title":"Kaohsiung J. Med. Sci."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"6786","DOI":"10.1182\/blood-2011-02-333997","article-title":"Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: Sustained efficacy and improved survival","volume":"117","author":"Kelly","year":"2011","journal-title":"Blood"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","article-title":"Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic\u2013Uremic Syndrome","volume":"368","author":"Legendre","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/ki.2014.423","article-title":"Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies","volume":"87","author":"Licht","year":"2015","journal-title":"Kidney Int."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s40620-016-0288-3","article-title":"Improved renal recovery in patients with atypical hemolytic uremic syndrome following rapid initiation of eculizumab treatment","volume":"30","author":"Walle","year":"2017","journal-title":"J. Nephrol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.kint.2015.11.026","article-title":"Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome","volume":"89","author":"Greenbaum","year":"2016","journal-title":"Kidney Int."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1053\/j.ajkd.2015.12.034","article-title":"Terminal Complement Inhibitor Eculizumab in Adult Patients With Atypical Hemolytic Uremic Syndrome: A Single-Arm, Open-Label Trial","volume":"68","author":"Fakhouri","year":"2016","journal-title":"Am. J. Kidney Dis."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Menne, J., Delmas, Y., Fakhouri, F., Licht, C., Lommel\u00e9, \u00c5., Minetti, E.E., Prov\u00f4t, F., Rondeau, E., Sheerin, N.S., and Wang, J. (2019). Outcomes in patients with atypical hemolytic uremic syndrome treated with eculizumab in a long-term observational study. BMC Nephrol., 20.","DOI":"10.1186\/s12882-019-1314-1"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1093\/ckj\/sfy035","article-title":"Eculizumab prevents thrombotic microangiopathy in patients with atypical haemolytic uraemic syndrome in a long-term observational study","volume":"12","author":"Menne","year":"2018","journal-title":"Clin. Kidney J."},{"key":"ref_52","unstructured":"Rondeau, E., Scully, M., Ariceta, G., Barbour, T.D., Cataland, S.R., Heyne, N., Miyakawa, Y., Ortiz, D., Swenson, E.D., and Vallee, M. (2019, January 5\u201310). TH-PO800: Efficacy and safety of the Long-acting C5-inhibitor ravulizumab in adult patients with atypical hemolytic uremic syndrome (aHUS). Proceedings of the American Society of Nephrology (ASN) Kidney Week 2019, Washington, DC, USA."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Licht, C., Ardissino, G., Ariceta, G., Cohen, D., Cole, J.A., Gasteyger, C., Greenbaum, L.A., Johnson, S., Ogawa, M., and Schaefer, F. (2015). The global aHUS registry: Methodology and initial patient characteristics. BMC Nephrol., 16.","DOI":"10.1186\/s12882-015-0195-1"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1016\/j.ekir.2019.07.016","article-title":"Eculizumab Safety: Five-Year Experience From the Global Atypical Hemolytic Uremic Syndrome Registry","volume":"4","author":"Rondeau","year":"2019","journal-title":"Kidney Int. Rep."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.kint.2018.02.029","article-title":"Clinical and genetic predictors of atypical hemolytic uremic syndrome phenotype and outcome","volume":"94","author":"Schaefer","year":"2018","journal-title":"Kidney Int."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Leanne, C., Rondeau, E., Ardissino, G., Caby-Tosi, M.-P., Al-Dakkak, I., Fakhouri, F., Miller, B., and Scully, M. (2019, January 13\u201316). SP075: Pregnancy outcomes in patients enrolled in the Global aHUS Registry. Proceedings of the 56th European Renal Association\u2014European Dialysis and Transplant Association (ERA-EDTA) Congress, Budapest, Hungary.","DOI":"10.1093\/ndt\/gfz103.SP075"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1007\/s10157-018-1610-2","article-title":"Safety and effectiveness of eculizumab for pediatric patients with atypical hemolytic-uremic syndrome in Japan: Interim analysis of post-marketing surveillance","volume":"23","author":"Ito","year":"2019","journal-title":"Clin. Exp. Nephrol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s10157-018-1609-8","article-title":"Safety and effectiveness of eculizumab for adult patients with atypical hemolytic-uremic syndrome in Japan: Interim analysis of post-marketing surveillance","volume":"23","author":"Kato","year":"2019","journal-title":"Clin. Exp. Nephrol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s10157-015-1142-y","article-title":"Efficacy and safety of eculizumab in childhood atypical hemolytic uremic syndrome in Japan","volume":"20","author":"Ito","year":"2016","journal-title":"Clin. Exp. Nephrol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1111\/imj.12864","article-title":"Atypical Haemolytic Uraemic Syndrome treated with the complement inhibitor Eculizumab: The experience of the Australian compassionate access cohort","volume":"45","author":"Mallett","year":"2015","journal-title":"Intern. Med. J."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"De Andrade, L.G.M., Contti, M.M., Nga, H.S., Bravin, A.M., Takase, H.M., Viero, R.M., Da Silva, T.N., Chagas, K.D.N., and Palma, L.M.P. (2017). Long-term outcomes of the Atypical Hemolytic Uremic Syndrome after kidney transplantation treated with eculizumab as first choice. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0188155"},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Besbas, N., Gulhan, B., Soylemezoglu, O., \u00d6z\u00e7akar, Z.B., Korkmaz, E., Hayran, M., and Ozaltin, F. (2017). Turkish pediatric atypical hemolytic uremic syndrome registry: Initial analysis of 146 patients. BMC Nephrol., 18.","DOI":"10.1186\/s12882-016-0420-6"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.transci.2016.09.017","article-title":"Efficacy and safety of eculizumab in adult patients with atypical hemolytic uremic syndrome: A single center experience from Turkey","volume":"55","author":"Gediz","year":"2016","journal-title":"Transfus. Apher. Sci."},{"key":"ref_64","unstructured":"Yenerel, M.N., Aktan, M., Yildiz, A., Caliskan, Y., and Nalcaci, M. (2014, January 6\u20139). 311-II-4: The importance of Eculizumab in patients with atypical Hemolytic Uremic Syndrome: Single center experience. Proceedings of the 56th American Society of Hematology (ASH) Annual Meeting, San Francisco, CA, USA."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1016\/j.kint.2019.01.023","article-title":"Atypical and secondary hemolytic uremic syndromes have a distinct presentation and no common genetic risk factors","volume":"95","author":"Delmas","year":"2019","journal-title":"Kidney Int."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1053\/j.ajkd.2013.07.011","article-title":"Insights From the Use in Clinical Practice of Eculizumab in Adult Patients With Atypical Hemolytic Uremic Syndrome Affecting the Native Kidneys: An Analysis of 19 Cases","volume":"63","author":"Fakhouri","year":"2014","journal-title":"Am. J. Kidney Dis."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"554","DOI":"10.2215\/CJN.04760512","article-title":"Genetics and Outcome of Atypical Hemolytic Uremic Syndrome: A Nationwide French Series Comparing Children and Adults","volume":"8","author":"Fakhouri","year":"2013","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1097\/TP.0000000000000601","article-title":"Use of Eculizumab in Patients With Allogeneic Stem Cell Transplant-Associated Thrombotic Microangiopathy: A study from the SFGM-TC","volume":"99","author":"Galambrun","year":"2015","journal-title":"Transplantation"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1111\/j.1600-6143.2008.02297.x","article-title":"Complement Mutation-AssociatedDe NovoThrombotic Microangiopathy Following Kidney Transplantation","volume":"8","author":"Lionet","year":"2008","journal-title":"Am. J. Transplant."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"3337","DOI":"10.1111\/j.1600-6143.2012.04252.x","article-title":"Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation","volume":"12","author":"Zuber","year":"2012","journal-title":"Am. J. Transplant."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/ki.2012.63","article-title":"Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies","volume":"82","author":"Servais","year":"2012","journal-title":"Kidney Int."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1093\/ndt\/gfw453","article-title":"Eculizumab in secondary atypical haemolytic uraemic syndrome","volume":"32","author":"Cavero","year":"2017","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.kint.2017.06.022","article-title":"A retrospective study of pregnancy-associated atypical hemolytic uremic syndrome","volume":"93","author":"Huerta","year":"2018","journal-title":"Kidney Int."},{"key":"ref_74","unstructured":"Cavero, T., de C\u00f3rdoba, S.R., and Praga, M. (2018, January 16\u201319). 121: \u00bfMicroangiopat\u00eda tromb\u00f3tica asociada a hipertensi\u00f3n o a hiperactividad del complemento? Implicaciones diagn\u00f3sticas y terap\u00e9uticas. Proceedings of the XLVIII Congreso de la Sociedad Espa\u00f1ola de Nefrolog\u00eda y IX Congreso Iberoamericano de Nefrolog\u00eda, Madrid, Spain."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/qjmed\/hcv082","article-title":"A national specialized service in England for atypical haemolytic uraemic syndrome-the first year\u2019s experience","volume":"109","author":"Sheerin","year":"2016","journal-title":"QJM"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/j.kint.2017.04.028","article-title":"Factor H autoantibody is associated with atypical hemolytic uremic syndrome in children in the United Kingdom and Ireland","volume":"92","author":"Brocklebank","year":"2017","journal-title":"Kidney Int."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1002\/mus.23839","article-title":"A randomized, double-blind, placebo-controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis","volume":"48","author":"Howard","year":"2013","journal-title":"Muscle Nerve"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): A phase 3, randomised, double-blind, placebo-controlled, multicentre study","volume":"16","author":"Howard","year":"2017","journal-title":"Lancet Neurol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/mus.26447","article-title":"Long-term safety and efficacy of eculizumab in generalized myasthenia gravis","volume":"60","author":"Muppidi","year":"2019","journal-title":"Muscle Nerve"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1111\/ajt.13663","article-title":"C1 Inhibitor in Acute Antibody-Mediated Rejection Nonresponsive to Conventional Therapy in Kidney Transplant Recipients: A Pilot Study","volume":"16","author":"Viglietti","year":"2016","journal-title":"Am. J. Transplant."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"3468","DOI":"10.1111\/ajt.13871","article-title":"Plasma-Derived C1 Esterase Inhibitor for Acute Antibody Mediated Rejection Following Kidney Transplantation: Results of a Randomized, Double-Blind, Placebo-Controlled Pilot Study","volume":"16","author":"Montgomery","year":"2016","journal-title":"Am. J. Transplant."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1111\/j.1600-6143.2011.03757.x","article-title":"Terminal Complement Inhibition Decreases Antibody-Mediated Rejection in Sensitized Renal Transplant Recipients","volume":"11","author":"Stegall","year":"2011","journal-title":"Am. J. Transplant."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/TP.0000000000000592","article-title":"A Phase I\/II Placebo-Controlled Trial of C1-Inhibitor for Prevention of Antibody-Mediated Rejection in HLA Sensitized Patients","volume":"99","author":"Vo","year":"2015","journal-title":"Transplantation"},{"key":"ref_84","unstructured":"Vo, A.A., Choi, J., Kahwaji, J., Puliyanda, D., Peng, A., Villicana, R., and Jordan, S. (2015, January 3\u20136). A194: Long-term analysis of a placebo-controlled trial of C1-INH for prevention of antibody-mediated rejection. Proceedings of the 2015 American Transplant Congress, Philadelphia, PA, USA."},{"key":"ref_85","unstructured":"Vo, A.A., Choi, J., Peng, A., Lim, K., Varanasi, L., Najjar, R., Huang, E., Puliyanda, D., and Jordan, S. (May, January 29). A50: Update of a placebo-controlled trial of C1 esterase inhibitor for prevention of antibody mediated rejection (ABMR) in highly-HLA sensitized patients. Proceedings of the 2017 American Transplant Congress, Chicago, IL, USA."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2876","DOI":"10.1111\/ajt.15364","article-title":"Safety and efficacy of eculizumab in the prevention of antibody-mediated rejection in living-donor kidney transplant recipients requiring desensitization therapy: A randomized trial","volume":"19","author":"Marks","year":"2019","journal-title":"Am. J. Transplant."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1111\/ajt.15397","article-title":"Safety and efficacy of eculizumab for the prevention of antibody-mediated rejection after deceased-donor kidney transplantation in patients with preformed donor-specific antibodies","volume":"19","author":"Glotz","year":"2019","journal-title":"Am. J. Transplant."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"e13129","DOI":"10.1111\/petr.13129","article-title":"A prospective randomized, controlled trial of eculizumab to prevent ischemia-reperfusion injury in pediatric kidney transplantation","volume":"22","author":"Kaabak","year":"2018","journal-title":"Pediatr. Transplant."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1111\/ajt.14767","article-title":"A phase I\/II, double-blind, placebo-controlled study assessing safety and efficacy of C1 esterase inhibitor for prevention of delayed graft function in deceased donor kidney transplant recipients","volume":"18","author":"Jordan","year":"2018","journal-title":"Am. J. Transplant."},{"key":"ref_90","first-page":"564","article-title":"Peritransplant eculizumab does not prevent delayed graft function in deceased donor kidney transplant recipients: Results of two randomized controlled pilot trials","volume":"20","author":"Akalin","year":"2019","journal-title":"Am. J. Transplant."},{"key":"ref_91","unstructured":"(2020, April 29). Prevention of Delayed Graft Function Using Eculizumab Therapy (PROTECT Study). ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02145182."},{"key":"ref_92","first-page":"1","article-title":"The Clinical Trials Portfolio for On-label and Off-label Studies of Eculizumab","volume":"180","author":"Kim","year":"2019","journal-title":"JAMA Intern. Med."},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Suarez, M.L.G., Thongprayoon, C., Mao, M.A., Leeaphorn, N., Bathini, T., and Cheungpasitporn, W. (2019). Outcomes of Kidney Transplant Patients with Atypical Hemolytic Uremic Syndrome Treated with Eculizumab: A Systematic Review and Meta-Analysis. J. Clin. Med., 8.","DOI":"10.3390\/jcm8070919"},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Moher, D., Tetzlaff, J., Tricco, A.C., Sampson, M., and Altman, D.G. (2007). Epidemiology and Reporting Characteristics of Systematic Reviews. PLoS Med., 4.","DOI":"10.1371\/journal.pmed.0040078"},{"key":"ref_95","unstructured":"(2020, April 29). Study of ALXN1210 in Children and Adolescents with Atypical Hemolytic Uremic Syndrome (aHUS). ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03131219?term=NCT03131219&draw=2&rank=1."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S0895-4356(00)00242-0","article-title":"Publication and related bias in meta-analysis: Power of statistical tests and prevalence in the literature","volume":"53","author":"Sterne","year":"2000","journal-title":"J. Clin. Epidemiol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1111\/ajt.14001","article-title":"Eculizumab Therapy for Chronic Antibody-Mediated Injury in Kidney Transplant Recipients: A Pilot Randomized Controlled Trial","volume":"17","author":"Kulkarni","year":"2016","journal-title":"Am. J. Transplant."}],"container-title":["Biomedicines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9059\/8\/9\/355\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:10:42Z","timestamp":1760177442000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9059\/8\/9\/355"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,16]]},"references-count":98,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2020,9]]}},"alternative-id":["biomedicines8090355"],"URL":"https:\/\/doi.org\/10.3390\/biomedicines8090355","relation":{},"ISSN":["2227-9059"],"issn-type":[{"value":"2227-9059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,16]]}}}